SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Into Possible Breaches Of Fiduciary Duty By Board Of Cornerstone Therapeutics, Inc. In Connection With Sale Of Company To Chiesi Farmaceutici S.p.A.

Levi & Korsinsky is investigating the Board of Directors of Cornerstone Therapeutics, Inc. (“Cornerstone” or the “Company”) (Nasdaq:CRTX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Chiesi Farmaceutici SpA (“Chiesi”).

Click here to learn more about the investigation http://zlk.9nl.com/cornerstone-therapeutics/, or call: 877-363-5972. There is no cost or obligation to you.

Under the terms of the transaction, Cornerstone shareholders will receive $9.50 for each share of Cornerstone stock they own. Chiesi currently owns 58% of Cornerstone’s outstanding common shares. The investigation concerns, among other things, whether the consideration to be paid to Cornerstone shareholders is unfair, inadequate, and substantially below the fair or inherent value of Cornerstone stock. In particular, at least one analyst set a price target for Cornerstone stock at $14.00 per share.

If you own Cornerstone common stock and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/cornerstone-therapeutics/.

Levi & Korsinsky is a national firm with offices in New York, New Jersey and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Copyright Business Wire 2010

If you liked this article you might like

Top Insider Trades: PSX YRCW CRTX IDIX

Top Insider Trades: PSX YRCW CRTX IDIX

5 Biotech Stocks Under $10 Making Big Moves

5 Biotech Stocks Under $10 Making Big Moves

4 Health Care Stocks Under $10 Close to Breakouts

4 Health Care Stocks Under $10 Close to Breakouts

Cornerstone Therapeutics Inc. Stock Upgraded (CRTX)

Cornerstone Therapeutics Inc. Stock Upgraded (CRTX)

31 Drugs Facing FDA Approval in 2012-2013

31 Drugs Facing FDA Approval in 2012-2013